Busulfan therapy of central nervous system xenografts in athymic mice.

Cancer Chemother Pharmacol 1994 ;35(2):127-31

Department of Pediatrics, Duke University Medical Center, Durham, NC 27710.

We evaluated the antitumor activity of busulfan against a panel of tumor cell lines and xenografts in athymic nude mice derived from childhood high-grade glioma, adult high-grade glioma, ependymoma, and medulloblastoma. Busulfan displayed similar activity against a panel of four medulloblastoma cell lines (D283 Med, Daoy, D341 Med, and D425 Med) and four corresponding sublines with laboratory-generated or clinically acquired resistance to 4-hydroperoxycyclophosphamide [D283 Med (4-HCR), Daoy (4-HCR), D341 Med (4-HCR), and D458 Med] and cross-resistance to melphalan. This is consistent with a nearly total lack of cross-resistance of busulfan to 4-hydroperoxycyclophosphamide. Busulfan was active in the therapy of all but one of the subcutaneous xenografts tested, with growth delays ranging from 14.3 days in D612 EP to 58.4 days in D528 EP. Busulfan produced statistically significant increases in the median survival of mice bearing intracranial D456 MG (66%-90%), D612 EP (18%-33%), and D528 EP (89%) xenografts. These studies suggest that busulfan may be active against medulloblastomas, high-grade gliomas, and ependymomas as well as against cyclophosphamide-resistant neoplasms.

Download full-text PDF

Source
http://link.springer.com/10.1007/BF00686634
Publisher Site
http://dx.doi.org/10.1007/BF00686634DOI Listing
January 1995
1 Read

Publication Analysis

Top Keywords

high-grade glioma
8
cell lines
8
med 4-hcr
8
xenografts athymic
8
d341 med
8
busulfan active
8
busulfan
7
med
5
cross-resistance busulfan
4
busulfan 4-hydroperoxycyclophosphamide
4
lack cross-resistance
4
total lack
4
consistent total
4
active therapy
4
4-hydroperoxycyclophosphamide busulfan
4
melphalan consistent
4
xenografts tested
4
tested growth
4
therapy subcutaneous
4
subcutaneous xenografts
4

References

(Supplied by CrossRef)

P Alexander et al.
Biochem Pharmacol 1960

LJ Arduino et al.
Cancer Chemother Rep 1967

P Bedford et al.
Cancer Chemother Pharmacol 1982

SH Bigner et al.
Cancer Genet Cytogenet 1985

SH Bigner et al.
Cancer Res 1990

CC Boring et al.
CA 1993

P Brookes et al.
Biochem J 1961

DE Bullard et al.
Neurosurgery 1979

CDR Dunn et al.
Exp Hematol 1974

CDR Dunn et al.
Chem Biol Interact 1970

E Frei et al.
1988

Similar Publications